These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11951149)

  • 1. Successful treatment of recurrent brief depression with reboxetine -- a single case analysis.
    Pezawas L; Stamenkovic M; Aschauer N; Moffat R; Kasper S
    Pharmacopsychiatry; 2002 Mar; 35(2):75-6. PubMed ID: 11951149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D; Bridgman K; Buis C
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phenomenology of recurrent brief depression with and without hypomanic features.
    Lövdahl H; Andersson S; Hynnekleiv T; Malt UF
    J Affect Disord; 2009 Jan; 112(1-3):151-64. PubMed ID: 18538858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Fava M; McGrath PJ; Sheu WP;
    J Clin Psychopharmacol; 2003 Aug; 23(4):365-9. PubMed ID: 12920412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label non-randomized versus double-blind randomized antidepressive treatment: what are the advantages of clinical decision over randomization?
    Deuschle M; Krumm B; Bindeballe N; Colla M; Hamann B; Lederbogen F; Gilles M; Heuser I
    Pharmacopsychiatry; 2004 Nov; 37(6):299-302. PubMed ID: 15551197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reboxetine addition in patients with mirtazapine-resistant depression: a case series.
    López-Muñoz F; Rubio G; Alamo C; García-García P; Pardo A
    Clin Neuropharmacol; 2006; 29(4):192-6. PubMed ID: 16855420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine treatment in patients with recurrent brief depression.
    Stamenkovic M; Blasbichier T; Riederer F; Pezawas L; Brandstätter N; Aschauer HN; Kasper S
    Int Clin Psychopharmacol; 2001 Jul; 16(4):221-6. PubMed ID: 11459336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent brief depression revisited.
    Pezawas L; Angst J; Kasper S
    Int Rev Psychiatry; 2005 Feb; 17(1):63-70. PubMed ID: 16194772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eighteen months of drug treatment for depression: predicting relapse and recovery.
    Mulder RT; Frampton CM; Luty SE; Joyce PR
    J Affect Disord; 2009 Apr; 114(1-3):263-70. PubMed ID: 18805590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escitalopram/reboxetine combination in depressed patients with substance use disorder.
    Camarasa X; Lopez-Martinez E; Duboc A; Khazaal Y; Zullino DF
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):165-8. PubMed ID: 15610962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT).
    van den Brink RH; van Melle JP; Honig A; Schene AH; Crijns HJ; Lambert FP; Ormel J
    Am Heart J; 2002 Aug; 144(2):219-25. PubMed ID: 12177637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reboxetine for the treatment of patients with Cocaine Dependence Disorder.
    Szerman N; Peris L; Mesías B; Colis P; Rosa J; Prieto A;
    Hum Psychopharmacol; 2005 Apr; 20(3):189-92. PubMed ID: 15799010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.
    Kasper S; Volz HP; Möller HJ; Dienel A; Kieser M
    Eur Neuropsychopharmacol; 2008 Nov; 18(11):803-13. PubMed ID: 18694635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.
    Pintor L; Baillès E; Valldeoriola F; Tolosa E; Martí MJ; de Pablo J
    Gen Hosp Psychiatry; 2006; 28(1):59-64. PubMed ID: 16377367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antidepressants consumption in the global population in France].
    Olié JP; Elomari F; Spadone C; Lépine JP
    Encephale; 2002; 28(5 Pt 1):411-7. PubMed ID: 12386542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open clinical trial of reboxetine in the treatment of social phobia.
    Atmaca M; Tezcan E; Kuloglu M
    J Clin Psychopharmacol; 2003 Aug; 23(4):417-9. PubMed ID: 12920422
    [No Abstract]   [Full Text] [Related]  

  • 19. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
    Spivak B; Strous RD; Shaked G; Shabash E; Kotler M; Weizman A
    J Clin Psychopharmacol; 2006 Apr; 26(2):152-6. PubMed ID: 16633143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.